Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 429

1.

Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.

Nagatomo Y, Yoshikawa T, Okamoto H, Kitabatake A, Hori M; J-CHF Investigators.

Circ J. 2018 Feb 23;82(3):691-698. doi: 10.1253/circj.CJ-17-0442. Epub 2017 Sep 7.

2.

Reaction of Thymidine with Hypobromous Acid in Phosphate Buffer.

Suzuki T, Kitabatake A, Koide Y.

Chem Pharm Bull (Tokyo). 2016;64(8):1235-8. doi: 10.1248/cpb.c16-00138.

3.

Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study.

Nagatomo Y, Yoshikawa T, Okamoto H, Kitabatake A, Hori M; Japanese Chronic Heart Failure Study Investigators.

J Card Fail. 2015 Mar;21(3):198-207. doi: 10.1016/j.cardfail.2014.12.005. Epub 2014 Dec 18.

PMID:
25528200
4.

Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study.

Okamoto H, Hori M, Matsuzaki M, Tsutsui H, Yamazaki T, Nagai R, Yoshikawa T, Fujio Y, Nonen S, Azuma J, Izumi T, Ohashi Y, Kitabatake A; J-CHF Investigators.

Int J Cardiol. 2013 Apr 5;164(2):238-44. doi: 10.1016/j.ijcard.2012.11.051. Epub 2012 Dec 12.

5.

The change in low-density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid.

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS.

J Atheroscler Thromb. 2012;19(7):673-9. Epub 2012 May 26.

6.

Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

J Atheroscler Thromb. 2012;19(2):194-204. Epub 2011 Dec 17.

7.

Doppler echocardiography in diastology: 35 years of Japanese contribution to its advancement and utility.

Nakatani S, Mikami T, Kitabatake A.

J Echocardiogr. 2011 Mar;9(1):1-8. doi: 10.1007/s12574-010-0065-6. Epub 2010 Sep 23. Review.

PMID:
27279088
8.

Relationships between plasma fatty acid composition and coronary artery disease.

Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

J Atheroscler Thromb. 2011;18(2):99-107. Epub 2010 Nov 17.

9.

Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease.

Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

Circ J. 2010 Jul;74(7):1451-7. Epub 2010 May 18.

10.

Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study.

Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H; Japanese Stable Angina Pectoris Study Investigators.

JACC Cardiovasc Interv. 2008 Oct;1(5):469-79. doi: 10.1016/j.jcin.2008.08.002.

11.

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan.

Atherosclerosis. 2009 Oct;206(2):535-9. doi: 10.1016/j.atherosclerosis.2009.03.029. Epub 2009 Apr 5.

PMID:
19447387
12.

Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.

Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y; JELIS Investigators.

Circ J. 2009 Jul;73(7):1283-90. Epub 2009 May 8.

13.

Experimental study of the relationship between perfluoro-octyl bromide emulsion and norepinephrine release in reperfusion arrhythmia: isolated guinea pig heart model.

Isaka M, Sakuma I, Shiiya N, Fukushima S, Nakai K, Kitabatake A, Yasuda K.

Ann Thorac Cardiovasc Surg. 2008 Dec;14(6):363-8.

PMID:
19131922
14.

Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination.

Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, Aizawa Y, Yamashita T, Atarashi H, Horie M, Ohe T, Doi Y, Shimizu A, Chishaki A, Saikawa T, Yano K, Kitabatake A, Mitamura H, Kodama I, Kamakura S.

Int J Cardiol. 2009 Oct 2;137(2):102-7. doi: 10.1016/j.ijcard.2008.06.029. Epub 2008 Aug 8.

PMID:
18691774
15.

Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan.

Atherosclerosis. 2008 Sep;200(1):135-40. doi: 10.1016/j.atherosclerosis.2008.06.003. Epub 2008 Jun 19. Erratum in: Atherosclerosis. 2009 May;204(1):233.

PMID:
18667204
16.

Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial.

Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan.

Stroke. 2008 Jul;39(7):2052-8. doi: 10.1161/STROKEAHA.107.509455. Epub 2008 May 1. Erratum in: Stroke. 2008 Sep;39(9): e149.

PMID:
18451347
17.

Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan.

Miura K, Matsumori A, Nasermoaddeli A, Soyama Y, Morikawa Y, Sakurai M, Kitabatake A, Nagai M, Inaba Y, Nakagawa H.

Circ J. 2008 Mar;72(3):343-8.

18.

Allograft inflammatory factor-1 augments macrophage phagocytotic activity and accelerates the progression of atherosclerosis in ApoE-/- mice.

Mishima T, Iwabuchi K, Fujii S, Tanaka SY, Ogura H, Watano-Miyata K, Ishimori N, Andoh Y, Nakai Y, Iwabuchi C, Ato M, Kitabatake A, Tsutsui H, Onoé K.

Int J Mol Med. 2008 Feb;21(2):181-7.

PMID:
18204784
19.

Induction of c-fos mRNA expression by pure pressure overload in cultured cardiac myocytes.

Sakai H, Urasawa K, Oyama N, Kaneta S, Saito T, Kitabatake A, Tsutsui H.

Int Heart J. 2007 May;48(3):359-67.

20.

Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy.

Kawai S, Kitabatake A, Tomoike H; Takotsubo Cardiomyopathy Group.

Circ J. 2007 Jun;71(6):990-2.

21.

[J-CHF Study].

Okamoto H, Kitabatake A, Tsutsui H.

Nihon Rinsho. 2007 Apr 28;65 Suppl 4:537-42. Review. Japanese. No abstract available.

PMID:
17508587
22.

Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy.

Nonen S, Okamoto H, Fujio Y, Takemoto Y, Yoshiyama M, Hamaguchi T, Matsui Y, Yoshikawa J, Kitabatake A, Azuma J.

Pharmacogenomics J. 2008 Feb;8(1):78-84. Epub 2007 Apr 3.

PMID:
17404580
23.

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators.

Lancet. 2007 Mar 31;369(9567):1090-8. Erratum in: Lancet. 2007 Jul 21;370(9583):220.

PMID:
17398308
24.

Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.

Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M.

Biol Pharm Bull. 2007 Mar;30(3):537-42.

25.

Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy.

Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A; Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan.

Circ J. 2007 Mar;71(3):327-30.

26.

Prevalence and clinical importance of spontaneous echo contrast within the carotid artery in patients with ischemic cerebrovascular disease.

Onozuka H, Muraki M, Mikami T, Yoshimoto T, Yoshizumi T, Kitaguchi M, Sugawara T, Tokuda K, Kaneko S, Kashiwaba T, Yamada S, Tsutsui H, Kitabatake A.

J Ultrasound Med. 2007 Feb;26(2):169-77.

PMID:
17255178
27.

S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts.

Asanuma H, Nakai K, Sanada S, Minamino T, Takashima S, Ogita H, Fujita M, Hirata A, Wakeno M, Takahama H, Kim J, Asakura M, Sakuma I, Kitabatake A, Hori M, Komamura K, Kitakaze M.

J Mol Cell Cardiol. 2007 May;42(5):924-30. Epub 2007 Jan 17.

PMID:
17234208
28.

Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study.

Nasermoaddeli A, Miura K, Matsumori A, Soyama Y, Morikawa Y, Kitabatake A, Inaba Y, Nakagawa H.

Heart. 2007 Jun;93(6):711-5. Epub 2006 Nov 3.

29.

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.

Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group.

Lancet. 2006 Sep 30;368(9542):1155-63.

PMID:
17011942
30.

Lower prevalence of circulating natural killer T cells in patients with angina: a potential novel marker for coronary artery disease.

Andoh Y, Fujii S, Iwabuchi K, Yokota T, Inoue N, Nakai Y, Mishima T, Yamashita T, Nakagawa T, Kitabatake A, Onoe K, Tsutsui H.

Coron Artery Dis. 2006 Sep;17(6):523-8.

PMID:
16905964
31.

Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.

Takekuma Y, Takenaka T, Kiyokawa M, Yamazaki K, Okamoto H, Kitabatake A, Tsutsui H, Sugawara M.

J Pharm Pharm Sci. 2006;9(1):101-12.

32.

Role of left ventricular regional diastolic abnormalities for global diastolic dysfunction in patients with hypertrophic cardiomyopathy.

Goto K, Mikami T, Onozuka H, Kaga S, Inoue M, Komatsu H, Komuro K, Yamada S, Tsutsui H, Kitabatake A.

J Am Soc Echocardiogr. 2006 Jul;19(7):857-64.

PMID:
16824994
33.

[Future perspectives of beta-blockers in chronic heart failure].

Okamoto H, Tsutsui H, Kitabatake A.

Nihon Rinsho. 2006 May;64(5):921-6. Review. Japanese.

PMID:
16689375
34.

Low HDL-cholesterol, hypertension and impaired glucose tolerance as predictors of acute myocardial infarction in northern area of Japan.

Oyama N, Sakuma I, Kishimoto N, Saijo Y, Sakai H, Urasawa K, Kitabatake A, Kishi R, Tsutsui H.

Hokkaido Igaku Zasshi. 2006 Jan;81(1):25-30.

PMID:
16528977
35.

Angiotensin converting enzyme inhibitors attenuated the expression of G-protein coupled receptor kinases in heart failure patients.

Oyama N, Urasawa K, Kaneta S, Sakai H, Saito T, Takagi C, Yoshida I, Kitabatake A, Tsutsui H.

Circ J. 2006 Mar;70(3):362-3.

36.

[Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging].

Inoue M, Fujii S, Taisei M, Furumoto T, Kaga S, Komatsu H, Goto K, Komuro K, Yamada S, Onozuka H, Kitabatake A, Tsutsui H.

J Cardiol. 2006 Jan;47(1):9-14. Japanese.

PMID:
16475468
37.

Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.

Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M; Japan Atrial Fibrillation Stroke Trial Group.

Stroke. 2006 Feb;37(2):447-51. Epub 2005 Dec 29.

PMID:
16385088
38.

Increased plasma concentrations of N-terminal pro-brain natriuretic peptide reflect the presence of mildly reduced left ventricular diastolic function in hypertension.

Furumoto T, Fujii S, Mikami T, Inoue M, Nishihara K, Kaga S, Imagawa S, Goto K, Komuro K, Yamada S, Onozuka H, Kitabatake A, Sobel BE.

Coron Artery Dis. 2006 Feb;17(1):45-50.

PMID:
16374141
39.

Downregulation of cyclin-dependent kinase inhibitor; p57(kip2), is involved in the cell cycle progression of vascular smooth muscle cells.

Nakano N, Urasawa K, Takagi Y, Saito T, Kaneta S, Ishikawa S, Higashi H, Tsutsui H, Hatakeyama M, Kitabatake A.

Biochem Biophys Res Commun. 2005 Dec 23;338(3):1661-7. Epub 2005 Oct 25.

PMID:
16259944
40.

Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF).

Hori M, Kitabatake A, Tsutsui H, Okamoto H, Shirato K, Nagai R, Izumi T, Yokoyama H, Yasumura Y, Ishida Y, Matsuzaki M, Oki T, Sekiya M; J-DHF Program Committee.

J Card Fail. 2005 Sep;11(7):542-7.

PMID:
16198251
41.

No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population.

Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y, Yoshiyama M, Takemoto Y, Yoshikawa J, Azuma J, Kitabatake A.

Br J Clin Pharmacol. 2005 Oct;60(4):414-7.

42.

Cardioprotective effect of perfluorochemical emulsion for cardiac preservation after six-hour cold storage.

Isaka M, Imamura M, Sakuma I, Shiiya N, Fukushima S, Nakai K, Kitabatake A, Yasuda K.

ASAIO J. 2005 Jul-Aug;51(4):434-9.

PMID:
16156310
43.

Experimental studies on artificial blood usage for hemodilution during cardiopulmonary bypass.

Isaka M, Sakuma I, Imamura M, Makino Y, Fukushima S, Nakai K, Shiiya N, Kenmotsu O, Kitabatake A, Yasuda K.

Ann Thorac Cardiovasc Surg. 2005 Aug;11(4):238-44.

PMID:
16148870
44.

Chronic beta-adrenergic receptor stimulation enhances the expression of G-Protein coupled receptor kinases, GRK2 and GRK5, in both the heart and peripheral lymphocytes.

Oyama N, Urasawa K, Kaneta S, Sakai H, Saito T, Takagi C, Yoshida I, Kitabatake A, Tsutsui H.

Circ J. 2005 Aug;69(8):987-90.

45.

Mural thrombus in an ectatic right coronary artery caused acute myocardial infarction at downstream coronary artery.

Urasawa K, Inoue N, Yokota T, Oyama N, Sakai H, Fujii S, Kitabatake A.

Int Heart J. 2005 Mar;46(2):313-6.

46.

Double SCN5A mutation underlying asymptomatic Brugada syndrome.

Yokoi H, Makita N, Sasaki K, Takagi Y, Okumura Y, Nishino T, Makiyama T, Kitabatake A, Horie M, Watanabe I, Tsutsui H.

Heart Rhythm. 2005 Mar;2(3):285-92.

47.

Effects of endothelin receptor antagonist on expression of AT1 and AT2 receptors in the heart of SHR-SP.

Jesmin S, Sakuma I, Togashi H, Yoshioka M, Hattori Y, Kitabatake A, Miyauchi T.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S59-63.

PMID:
15838360
48.

The calcium channel antagonist benidipine reduces plasma and cardiac endothelin-1 levels in type II diabetic rat model.

Jesmin S, Sakuma I, Hattori Y, Kitabatake A, Miyauchi T.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S49-53.

PMID:
15838356
49.

Brain expression of VEGF and its receptors in SHR-SP and effects of an endothelin blocker.

Jesmin S, Sakuma I, Togashi H, Yoshioka M, Hattori Y, Kitabatake A, Miyauchi T.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S160-4.

PMID:
15838270
50.

Expression of endothelin receptors in the brain of SHR-SP and effects of an endothelin blocker.

Jesmin S, Sakuma I, Togashi H, Yoshioka M, Hattori Y, Kitabatake A, Miyauchi T.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S156-9.

PMID:
15838268

Supplemental Content

Loading ...
Support Center